News | July 10, 2007

St. Jude Medical Announces First Enrollment in Anti-Clotting Study

July 11, 2007- St. Jude Medical Inc. and the Duke Clinical Research Institute (DCRI) announced the first enrollment in a major study designed to better understand appropriate anti-clotting medication therapies for patients following implantation of tissue heart valves.
The study will gather extensive clinical evidence on the use of anti-coagulant and anti-platelet (blood-thinning) medication treatments to reduce the risk of clot formation in the early months after a tissue valve is implanted. It also will gather data on the incidence of clotting and bleeding experienced by patients during the six months after they receive a tissue valve.
Administered by the DCRI, the Anti-coagulation Strategy with Bioprosthetic Valves: Post-Operative Event Registry (ANSWER) will enroll at least 2,000 patients at 100 U.S. medical centers. Enrollment is expected to be completed over the next two years.
When complete, the ANSWER Registry is expected to provide the largest body of prospective clinical evidence, to date, on anti-clotting therapies prescribed following implantation of tissue valves. The ANSWER Registry will collect data from consenting adult patients who are receiving their first aortic and/or mitral valve replacement and are implanted with a St. Jude Medical Biocor or Biocor Supra Stented Tissue Valve. Similar clinical evidence is being collected in European centers through the ACTION Registry (Anticoagulation Treatment Influence on Postoperative Patients), initiated in 2006 and conducted by St. Jude Medical.

For more information:

Related Content

Abbott has pulled the Absorb Bioresorbable scaffold stent off the market.

The biggest cardiac technology story in September was Abbott pulled the Absorb Bioresorbable scaffold stent off the market because poor sales.

Feature | October 02, 2017
October 2, 2017 — Here is the list of the most popular articles and videos on the Diagnostic and Interventional Cardi
Biotronik Studies Demonstrate Efficacy of Minimizing Metal Burden in SFA Therapy
News | Stents Bare Metal| September 22, 2017
Physicians demonstrated that reducing metal burden in superficial femoral artery (SFA) therapy could effectively reduce...
Tryton Side Branch Stent Recognized With Premier Technology Breakthrough Award
News | Stents Bifurcation| September 21, 2017
September 21, 2017 — Cardinal Health and Tryton Medical Inc.
Abbott will end sales of the Absorb bioresorbable stent scaffold, pulling it off the market September 14, 2017.
Feature | Stents Bioresorbable| September 08, 2017 | Dave Fornell
September 8, 2017 — Abbott Vascular has announced it will end commercial sales of its Absorb bioresorbable vascular s
Biotronik's Orsiro Drug-Eluting Stent Outperforms Xience in BIOFLOW-V Trial
News | Stents Drug Eluting| September 01, 2017
September 1, 2017 — Biotronik recently announced data from the BIOFLOW-V randomized trial comparing Orsiro and Xience
FDA Approves Six-Month Primary Endpoint for Tack Endovascular System in Below the Knee Disease
News | Stents Peripheral| July 14, 2017
Intact Vascular Inc. announced the U.S. Food and Drug Administration (FDA) approved an Investigational Device Exemption...
Onyx DES 2.0 mm stent meets primary endpoints in small vessels
News | June 12, 2017
June 12, 2017 – The Medtronic Resolute Onyx Drug-Eluting Stent (DES) met its primary endpoint of target lesion failur
First Pennsylvania Patient Treated in LEADERS FREE II Trial of BioFreedom Drug-Coated Stent
News | Stents Drug Eluting| May 12, 2017
PinnacleHealth CardioVascular Institute enrolled the first patient in Pennsylvania in a trial assessing the safety and...
Resolute Onyx DES, drug eluting stent, medtronic, gains FDA approval
Technology | Stents Drug Eluting| May 01, 2017
May 1, 2017 — The U.S.
Overlay Init